214 related articles for article (PubMed ID: 12428815)
1. Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction.
Ferguson JJ
Clin Cardiol; 2002 Nov; 25(11 Suppl 1):I16-22. PubMed ID: 12428815
[TBL] [Abstract][Full Text] [Related]
2. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
Magee KD; Sevcik W; Moher D; Rowe BH
Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
Wong GC; Giugliano RP
Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Kereiakes DJ; Montalescot G; Antman EM; Cohen M; Darius H; Ferguson JJ; Grines C; Karsch KR; Kleiman NS; Moliterno DJ; Steg PG; Teirstein P; Van de Werf F; Wallentin L
Am Heart J; 2002 Oct; 144(4):615-24. PubMed ID: 12360156
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Kaul S; Shah PK
J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
[TBL] [Abstract][Full Text] [Related]
8. Heparin versus placebo for non-ST elevation acute coronary syndromes.
Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin.
Antman EM; Kereiakes DJ
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E1-4;discussion E25-8. PubMed ID: 11156721
[TBL] [Abstract][Full Text] [Related]
10. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Husted SE; Nielsen HK
Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins and coronary artery disease.
Zed PJ
Curr Cardiol Rep; 2000 Jan; 2(1):61-8. PubMed ID: 10980874
[TBL] [Abstract][Full Text] [Related]
12. The role of low-molecular-weight heparins in cardiovascular medicine.
Hödl R; Klein W
J Clin Pharm Ther; 2003 Oct; 28(5):371-8. PubMed ID: 14632961
[TBL] [Abstract][Full Text] [Related]
13. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
14. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
[TBL] [Abstract][Full Text] [Related]
15. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
[TBL] [Abstract][Full Text] [Related]
16. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions?
Fry ET
Clin Cardiol; 2001 Mar; 24(3 Suppl):I8-11. PubMed ID: 11286313
[TBL] [Abstract][Full Text] [Related]
18. The role of low-molecular-weight heparin in the management of acute coronary syndromes.
Cohen M
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):55S-61S. PubMed ID: 12644342
[TBL] [Abstract][Full Text] [Related]
19. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
20. Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Chiquette E; Chilton R
Curr Atheroscler Rep; 2004 Mar; 6(2):94-100. PubMed ID: 15023292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
